ProKidney Corp - Class A
Research ProKidney Corp - Class A (PROK) on Bullrun: market cap USD 343.55M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPROK
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 343.55M
- Financial periodQ2 2026
- RevenueUSD 150.00K
- Net income-USD 28.42M
- Free cash flow-USD 44.21M
Valuation Snapshot
latest market cap is USD 343.55M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 893.00K | -USD 68.99M | -USD 135.31M | n/a | -0.52 | USD 108.54M | USD 4.04M | -USD 1.01B |
| FY2024 | USD 76.00K | -USD 61.19M | -USD 155.86M | n/a | -0.62 | USD 99.12M | USD 3.24M | -USD 994.95M |
| FY2023 | USD 0 | -USD 35.47M | -USD 124.27M | n/a | -0.57 | USD 60.65M | USD 4.41M | -USD 1.10B |
| FY2022 | USD 0 | -USD 148.14M | -USD 78.94M | n/a | -0.23 | USD 490.25M | USD 2.40M | -USD 1.10B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 343.55M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 317.65M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 216.41M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 120.84M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 422.17M | n/a | n/a | n/a |
About ProKidney Corp - Class A
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is ProKidney Corp - Class A's market cap?
ProKidney Corp - Class A's market capitalization is USD 343.55M.
What does ProKidney Corp - Class A do?
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.